Abstract
Several cholinesterase (ChE) inhibitors have been labeled with carbon-11 for visualizing binding sites on acetylcholinesterase (AChE) by positron emission tomography (PET). Following intravenous injection of 1,2,3,4- tetrahydro-9-[11C]methylaminoacridine or [11C]donepezil, however, the radioactivity distribution does not reflect the regional distribution of AChE in the brain of animals, probably because these compounds have high non-specific binding and / or other specific binding sites in vivo in the brain. PET studies with [11C]physostigmine and [11C]CP-126,998 in the brain of healthy subjects have shown a radioactivity distribution corresponding to the regional distribution of AChE activity measured in postmortem human brains. These radiotracers may be useful for measuring the occupancy of binding sites on AChE by AChE inhibitors, and for investigating the cerebral pharmacokinetics of such therapeutic drugs. An alternative approach to map AChE is the use of acetylcholine analogue substrates. We have developed Nmethylpiperidinyl esters labeled with carbon-11 for quantitative measurement of AChE activity. Currently, two N- [11C]methylpiperidine esters, N-[11C]methylipiperidin-4-ylacetate (MP4A) and N-[11C]methylpiperidin-4-yl propionate (MP4P or PMP), have been used for clinical studies of Alzheimers disease and other neurodegenerative diseases. Both [11C]MP4A- and [11C]MP4P-PET have demonstrated not only the reduction of AChE activity in the cerebral cortex of patients with Alzheimers disease (AD) but also the inhibitory effects of donepezil and rivastigmine on AChE activity in the brain of AD patients. AChE imaging should prove useful for therapeutic monitoring of the effects of ChE inhibitors, including determination of the appropriate clinical doses of newly developed compounds, and can thus prompt the development of novel drugs targeting AChE.
Keywords: acetylcholine, acetylcholinesterase, butyrylcholinesterase, positron emission tomography, alzheimer disease, donepezil, physostigmine, rivastigmine
Current Pharmaceutical Design
Title: Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design
Volume: 10 Issue: 13
Author(s): Hitoshi Shinotoh, Kiyoshi Fukushi, Shin-ichiro Nagatsuka and Toshiaki Irie
Affiliation:
Keywords: acetylcholine, acetylcholinesterase, butyrylcholinesterase, positron emission tomography, alzheimer disease, donepezil, physostigmine, rivastigmine
Abstract: Several cholinesterase (ChE) inhibitors have been labeled with carbon-11 for visualizing binding sites on acetylcholinesterase (AChE) by positron emission tomography (PET). Following intravenous injection of 1,2,3,4- tetrahydro-9-[11C]methylaminoacridine or [11C]donepezil, however, the radioactivity distribution does not reflect the regional distribution of AChE in the brain of animals, probably because these compounds have high non-specific binding and / or other specific binding sites in vivo in the brain. PET studies with [11C]physostigmine and [11C]CP-126,998 in the brain of healthy subjects have shown a radioactivity distribution corresponding to the regional distribution of AChE activity measured in postmortem human brains. These radiotracers may be useful for measuring the occupancy of binding sites on AChE by AChE inhibitors, and for investigating the cerebral pharmacokinetics of such therapeutic drugs. An alternative approach to map AChE is the use of acetylcholine analogue substrates. We have developed Nmethylpiperidinyl esters labeled with carbon-11 for quantitative measurement of AChE activity. Currently, two N- [11C]methylpiperidine esters, N-[11C]methylipiperidin-4-ylacetate (MP4A) and N-[11C]methylpiperidin-4-yl propionate (MP4P or PMP), have been used for clinical studies of Alzheimers disease and other neurodegenerative diseases. Both [11C]MP4A- and [11C]MP4P-PET have demonstrated not only the reduction of AChE activity in the cerebral cortex of patients with Alzheimers disease (AD) but also the inhibitory effects of donepezil and rivastigmine on AChE activity in the brain of AD patients. AChE imaging should prove useful for therapeutic monitoring of the effects of ChE inhibitors, including determination of the appropriate clinical doses of newly developed compounds, and can thus prompt the development of novel drugs targeting AChE.
Export Options
About this article
Cite this article as:
Shinotoh Hitoshi, Fukushi Kiyoshi, Nagatsuka Shin-ichiro and Irie Toshiaki, Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design, Current Pharmaceutical Design 2004; 10 (13) . https://dx.doi.org/10.2174/1381612043384763
DOI https://dx.doi.org/10.2174/1381612043384763 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Understanding of Central Nervous System Drainage Systems: Implications in the Context of Neurodegenerative Diseases
Current Neuropharmacology Lentiviral Vector-Based Models of Amyloid Pathology: From Cells to Animals
Current Alzheimer Research Synthesis and Evaluation of Chalcone and its Derivatives as Potential Anticholinergic Agents
Letters in Drug Design & Discovery Novel Targets for Drugs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors
Current Topics in Medicinal Chemistry Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry Pathogenesis of Abeta Oligomers in Synaptic Failure
Current Alzheimer Research Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Physical Activity and Urinary Incontinence in Older Adults: A Community-Based Study
Current Aging Science Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment
Current Alzheimer Research Vitamin D and Subjective Memory Complaint in Community-Dwelling Older Adults
Current Alzheimer Research Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Obesity Promotes Oxidative Stress and Exacerbates Sepsis-induced Brain Damage
Current Neurovascular Research Drusen in the Peripheral Retina of the Alzheimer’s Eye
Current Alzheimer Research Interactions of Ginkgolides A and B with a Recombinant Human Prion Protein
Protein & Peptide Letters